|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | European Organization for Research and Treatment of Cancer - EORTC |
|---|---|
| Information provided by: | National Cancer Institute (NCI) |
| ClinicalTrials.gov Identifier: | NCT00003029 |
Purpose
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving drugs in different ways may kill more tumor cells. It is not yet known whether fluorouracil plus cisplatin are more effective than fluorouracil alone in treating patients with metastatic cancer of the pancreas.
PURPOSE: Randomized phase III trial to compare the effectiveness of fluorouracil with or without cisplatin in treating patients who have advanced or metastatic cancer of the pancreas.
| Condition | Intervention | Phase |
|---|---|---|
|
Pancreatic Cancer |
Drug: cisplatin Drug: fluorouracil |
Phase III |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Primary Purpose: Treatment |
| Official Title: | Infusional 5-Fluorouracil With or Without Cisplatin and With or Without Chronomodulation Against Locally-Advanced or Metastatic Pancreatic Cancer. A Multicenter Randomized Phase III Trial. |
| Estimated Enrollment: | 200 |
| Study Start Date: | May 1997 |
OBJECTIVES:
OUTLINE: This is a multicenter, randomized study.
The study design is a 2 X 2 factorial such that patients are allocated to one of 4 treatment groups involving the use or absence of chronomodulation and cisplatin (CDDP). Treatment in each of the 4 groups is repeated for 3 courses where each course is a 5-day course of treatment.
Patients in the first group receive a chronomodulated schedule based on delivery of fluorouracil (FU). Patients in the second group receive a chronomodulated schedule of FU and CDDP. Patients in the third and fourth experimental groups receive flat schedules of FU alone or FU and CDDP, respectively. Dosages of FU are increased across the three courses whereas dosages of CDDP remain constant.
Treatment is continued until disease progression, severe toxicity, or complete remission for more than 4 months occurs.
PROJECTED ACCRUAL: 200 patients will be accrued.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
PATIENT CHARACTERISTICS:
Age:
Performance status:
Hematopoietic:
Hepatic:
Renal:
Cardiovascular:
Other:
PRIOR CONCURRENT THERAPY:
Biologic therapy:
Chemotherapy:
Endocrine therapy:
Radiotherapy:
Surgery:
Contacts and Locations| Belgium | |
| Hopital de Jolimont | |
| Haine Saint Paul, Belgium, 7100 | |
| Les Cliniques Saint-Joseph ASBL | |
| Liege, Belgium, B 4000 | |
| France | |
| Centre Hospitalier de la Cote Basque | |
| Bayonne, France, 64109 | |
| Centre Jean Perrin | |
| Clermont-Ferrand, France, 63011 | |
| Centre de Lutte Contre le Cancer, Georges-Francois Leclerc | |
| Dijon, France, 21079 | |
| Hopital Perpetuel Secours | |
| Levallois-Perret, France, 92300 | |
| Centre Hospital Regional Universitaire de Limoges | |
| Limoges, France, 87042 | |
| Hopital Notre-Dame de Bon Secours | |
| Metz, France, 55038 | |
| Centre Hospitalier de Montlucon | |
| Montlucon, France, 03109 | |
| Clinique Hartmann | |
| Neuilly sur Seine, France, 92200 | |
| Hopital Saint-Louis | |
| Paris, France, 75475 | |
| Hopital Cochin | |
| Paris, France, 75674 | |
| Centre Rene Huguenin | |
| Saint Cloud, France, 92211 | |
| Hopital Bellevue | |
| Saint Etienne, France, 42055 | |
| Clinique de l'Orangerie | |
| Strasbourg, France, 67010 | |
| Hopital Paul Brousse | |
| Villejuif, France, 94804 | |
| Israel | |
| Wolfson Medical Center | |
| Holon, Israel, 58100 | |
| Italy | |
| Universita G.D'Annunzio Di Chieti | |
| Chieti, Italy, 66100 | |
| Portugal | |
| Hospital Fernando Fonseca | |
| Amadora, Portugal, P-2700 | |
| Investigator: | Francis Levi, MD, PhD | Institut de Cancerologie et D'Immunogenetique at Hopital Paul-Brousse |
More Information
| ClinicalTrials.gov Identifier: | NCT00003029 History of Changes |
| Other Study ID Numbers: | CDR0000065623, EORTC-05962 |
| Study First Received: | November 1, 1999 |
| Last Updated: | July 23, 2008 |
| Health Authority: | United States: Federal Government |
|
stage III pancreatic cancer adenocarcinoma of the pancreas stage IV pancreatic cancer |
|
Pancreatic Neoplasms Digestive System Neoplasms Neoplasms by Site Neoplasms Endocrine Gland Neoplasms Digestive System Diseases Pancreatic Diseases Endocrine System Diseases Cisplatin Fluorouracil |
Antineoplastic Agents Therapeutic Uses Pharmacologic Actions Radiation-Sensitizing Agents Physiological Effects of Drugs Antimetabolites Molecular Mechanisms of Pharmacological Action Antimetabolites, Antineoplastic Immunosuppressive Agents Immunologic Factors |